SPTX

18.1450.96%
AL

Antony Loebel

Chief Medical Officer & President of Clinical Development

Dr. Antony Loebel, also known as Tony, M.D., serves as Chief Medical Officer and President of Clinical Development of Seaport Therapeutics, Inc. since June 2024. He had been President and Chief Executive Officer of Sunovion Pharmaceuticals Inc. since April 1, 2019 and has been its Director. He has been Executive Officer at Sumitomo Dainippon Pharma Co. Ltd. since Apirl 1, 2012. Dr. Loebel served as the Chief Medical Officer, Executive Vice President and Head of Global Clinical Development at Sunovion Pharmaceuticals Inc. until April 1, 2019 and served as its Executive Vice President of Clinical Research & Medical Affairs. He joined Sunovion Pharmaceuticals Inc. in 2007. Dr. Loebel led the global development of LATUDA® (lurasidone HCl), ensuring its successful U.S. NDA regulatory filing and subsequent approval by the U.S. FDA. Dr. Loebel worked at Pfizer as Senior Medical Director and Team Leader for the U.S. Geodon® (ziprasidone) franchise. He was responsible for oversight of clinical strategy, lifecycle development, clinical trials, marketing support, publications programs and independent investigator research programs for this CNS therapy. He worked at Pfizer Inc. in drug development and medical affairs roles from 2001 to 2007. Dr. Loebel is a board-certified psychiatrist whose background includes clinical practice, clinical research and program development, he heads medical affairs and clinical research initiatives for all commercialized and development stage products at Sunovion. He has been Independent Director of HighCape Capital Acquisition Corp. since September 3, 2020. Dr. Loebel also serves on the board of directors of the Pharmaceutical Research and Manufacturers of America (PhRMA) and HighCape I. Dr. Loebel has published more than 50 scientific peer-reviewed articles or book chapters in psychiatry, as well as approximately 300 abstracts or posters. Dr. Loebel is a clinical assistant professor of psychiatry at the New York University School of Medicine, a Fellow of the American Psychiatric Association (APA) and a Fellow of the American College of Neuropsychopharmacology (ACNP). For his achievements in advancing new treatments for central nervous system disorders, Dr. Loebel received the 2015 Award for Leadership from the International Society for CNS Drug Development (ISCDD) and the 2019 CNS Summit Leadership Award. He was also selected by PharmaVOICE in 2019 and 2013 as one of the “100 Most Inspiring People” in the pharmaceutical industry. Dr. Loebel earned a M.D. from the University of Washington School of Medicine in Seattle. He completed his residency in Psychiatry and a research fellowship in Clinical Neurosciences at Zucker Hillside Hospital in Glen Oaks, New York. Dr. Loebel received a B.A. from the University of Washington.

Positions